HER2 positive breast cancerMETASTATIC breast cancerCLINICAL trialsPROGRESSION-free survivalBackground: Human epidermal growth factor receptor 2 protein (HER2)- positive ( ) metastatic breast cancer (MBC) is an aggressive disease and patients often undergo multiple lines of therapy f...
but you might receive it before surgery to help shrink your tumor in some cases. Chemotherapy is a treatment option for most forms of breast cancer. It can be used for treating early and locally advanced breast cancer as well as metastatic disease. Chemotherapy might also be calledantineoplastic...
EXTH-63. FOCUSED ULTRASOUND HYPERTHERMIA MEDIATED CONTROL OF THERMAL RESPONSIVE CAR T CELL ACTIVITY IN BREAST CANCER BRAIN METASTASIS HER2-targeted therapies are promising treatment options for metastatic breast cancer and have improved the median overall survival. However, breast cancer ... K Chulyong...
Find information about Herceptin® (trastuzumab), a treatment for HER2+ early and metastatic breast cancer and stomach cancer/GEJ. See full safety & Boxed Warnings for more information.
Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin. Breast Cancer. 2008, 8, S61-70.B Overmoyer.Options for the treatment of patients with taxane-refractory metastatic breast cancer.Clinical Breast Cancer. 2008...
Breast cancer is the most common malignancy in women, accounting for about 270,000 cases a year. The average woman has about a 12% chance of developing breast cancer.
During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed biomarker testing and treatment exposure for a patient with metastatic breast cancer in the second article of a 2-part series.
“The other scenario, [however,] is where somebody with DCIS will have the disease progress to invasive breast cancer, with even… [progression to] metastatic disease. [Clearly, that] could potentially impair quality of life and survival for the individual, and thus treating DCIS [more aggressiv...
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer...
For many years, tamoxifen was the mainstay of treatment for hormone receptor-positive metastatic breast cancer (MBC). However, in recent years, newer endocrine agents, particularly aromatase inhibitors, have consistently proved their superiority over tamoxifen by improving clinical outcomes. These agents...